Efficacy of Satralizumab As Monotherapy in Pre-Specified Subgroups of Sakurastar, a Double-Blind Placebo-Controlled Phase 3 Clinical Study in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Jeffrey L Bennett,Benjamin Greenberg,Anthony Traboulsee,Lech Szczechowski,Edward Fox,Svitlana Shkrobot,Takashi Yamamura,Yusuke Terada,Yuichi Kawata,Pádraig Wright

doi:10.1016/j.msard.2019.11.051

Efficacy of Satralizumab As Monotherapy in Pre-Specified Subgroups of Sakurastar, a Double-Blind Placebo-Controlled Phase 3 Clinical Study in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Jeffrey L Bennett, Benjamin Greenberg + Show 8 more

Open Access

https://doi.org/10.1016/j.msard.2019.11.051

Copy DOI

Journal: Multiple Sclerosis and Related Disorders	Publication Date: Jan 1, 2020
Citations: 1

Affiliation: University of Colorado Denver, The University of Texas Southwestern Medical Center, University of British Columbia, Central Texas Neurology Consultants, I.Horbachevsky Ternopil National Medical University, National Center of Neurology and Psychiatry, Roche (Switzerland)

#Neuromyelitis Optica Spectrum Disorder #Risk Of Relapse In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Interleukin-6 (IL-6) is a pro-inflammatory cytokine implicated in the immune pathology of neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD). Satralizumab, a humanised recycling monoclonal antibody that binds to the IL-6 receptor, reduced risk of relapse in patients with NMO or NMOSD as add-on therapy in the SAkuraSky study (NCT02028884) and monotherapy in the SAkuraStar study (NCT02073279).

Full Text